{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:58Z","timestamp":1793383018792,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Diabetes is a metabolic disorder characterized by hyperglycemia and is associated with several comorbidities and complications. Genital infection is one such complication that is often associated with diabetes mellitus (DM). Even though abnormalities in immune system, high urine glucose, and bladder dysfunction are important contributors for the increased risk of genitourinary symptoms, yet the possible role of pharmacologically induced glucosuria cannot be completely overlooked in such patients. There are various classes of medications to control blood glucose levels. A new therapeutic option to manage hyperglycemia is to increase renal glucose excretion by inhibiting sodium-glucose cotransporter-2 (SGLT2) glucose transport proteins. SGLT2 inhibitors (SGLT2i) represent a novel class of oral antidiabetic drugs which are associated with drug-induced glucosuria. Currently, canagliflozin, dapagliflozin, and empagliflozin are the three SGLT2i approved for therapy in Type 2 DM (T2DM). Safety studies with these three SGLT2i have reported events of mild-moderate genital infections in patients on SGLT2i therapy. However, most of the reported infections responded to standard treatment. Apart from SGLT2i, factors including personal hygiene, menopause, and circumcision might have a possible role in reported events of genital infections among T2DM patients on SGLT2i therapy. The present review identifies the occurrence of genital infections in diabetic patients on SGLT2i therapy, factors affecting the incidence of genital infections, and management strategies in patients with T2DM on SGLT2i therapy.<\/jats:p>","DOI":"10.4103\/ijem.ijem_159_17","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T03:43:00Z","timestamp":1543894980000},"page":"837-842","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":95,"title":["Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.4103","volume":"22","author":[{"given":"A. G.","family":"Unnikrishnan","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Chellaram Diabetes Institute, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bharti Research Institute of Diabetes, Bharti Hospital, Karnal, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedavati","family":"Purandare","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chellaram Diabetes Institute, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Vasnawala","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca Pharma India Ltd., Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 2","key":"R1-20260327","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.cmi.2015.03.024","article-title":"Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: Focus on skin and soft-tissue infections","volume":"21","author":"Dryden","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/jinf.2000.0723","article-title":"Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status","volume":"41","author":"Goswami","year":"2000","journal-title":"J Infect"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2013.05.2650","article-title":"Genital mycotic infections in patients with diabetes","volume":"125","author":"Nyirjesy","year":"2013","journal-title":"Postgrad Med"},{"key":"R5-20260327","first-page":"74","article-title":"Study on various types of infections related to balanitis in circumcised or uncircumcised male and its causes, symptoms and management","volume":"6","author":"Rajiah","year":"2012","journal-title":"Afr J Pharm Pharmacol"},{"key":"R6-20260327","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7243\/2050-0866-2-5","article-title":"Prevalence and recurrence of urinary tract and genital infections among adults with and without type 2 diabetes mellitus in the general population: A longitudinal cohort study","volume":"2","author":"Grandy","year":"2013","journal-title":"J Diabetes Res Clin Metab"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.26.2.510","article-title":"Quantifying the risk of infectious diseases for people with diabetes","volume":"26","author":"Shah","year":"2003","journal-title":"Diabetes Care"},{"key":"R8-20260327","first-page":"834","article-title":"Prevalence of vaginal candidiasis in diabetic women of Madhya Pradesh, India","volume":"4","author":"Shrivastav","year":"2015","journal-title":"Int J Curr Microbiol Appl Sci"},{"issue":"Suppl 1","key":"R9-20260327","first-page":"S27","article-title":"Infections in patients with diabetes mellitus: A review of pathogenesis","volume":"16","author":"Casqueiro","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jdiacomp.2012.06.012","article-title":"Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database","volume":"26","author":"Hirji","year":"2012","journal-title":"J Diabetes Complications"},{"key":"R13-20260327","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: Considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R15-20260327","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4103\/2230-8210.139206","article-title":"Medication counselling with sodium glucose transporter 2 inhibitor therapy","volume":"18","author":"Kalra","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"R17-20260327","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","article-title":"Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"28","author":"Nyirjesy","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R18-20260327","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: A randomized double-blind placebo-controlled 102-week trial","volume":"32","author":"Bailey","year":"2015","journal-title":"Diabet Med"},{"key":"R19-20260327","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R20-20260327","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R21-20260327","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/00325481.2016.1167570","article-title":"Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes","volume":"128","author":"Arakaki","year":"2016","journal-title":"Postgrad Med"},{"key":"R22-20260327","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/2230-8210.179996","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India","volume":"20","author":"Prasanna Kumar","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"R23-20260327","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0034-1374997","article-title":"Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials","volume":"9","author":"Kim","year":"2014","journal-title":"Diabetologie und Stoffwechsel"},{"key":"R24-20260327","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R25-20260327","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jsbmb.2013.09.003","article-title":"The immune system in menopause: Pros and cons of hormone therapy","volume":"142","author":"Ghosh","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"R26-20260327","first-page":"A276","article-title":"Genital mycotic infections with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM)","volume":"62","author":"Nyirjesy","year":"2013","journal-title":"Diabetes"},{"key":"R27-20260327","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12649","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"R28-20260327","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/dom.12047","article-title":"Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: A phase II multicentre, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Kaku","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R29-20260327","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R30-20260327","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1701-2163(15)30316-9","article-title":"Vulvovaginitis: Screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis","volume":"37","author":"van Schalkwyk","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"issue":"Suppl 3","key":"R32-20260327","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1258\/0956462011923976","article-title":"European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of balanoposthitis","volume":"12","author":"Edwards","year":"2001","journal-title":"Int J STD AIDS"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223308-201822060-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:38:44Z","timestamp":1787837924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223308-201822060-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_159_17","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}